Search

For the sensorless control in a low-speed range of synchronous reluctance motors (SynRMs), injecting random high-frequency (HF) square-wave-type voltages has become a widely used and technologically mature method. It can solve the noise problem of traditional injection signal methods. However, all injection signal methods will cause problems such as torque ripple, which causes speed fluctuations. This article proposes a self-regulating random model algorithm for the random injection signal method, which includes a quantity adaptive module for adding additional random processes, an evaluation module for evaluating torque deviation degree, and an updated model module that is used to receive signals from the other two modules and complete model changes and output random model elements. The main function of this algorithm is to create a model that updates to suppress the evaluation value deviation based on the evaluation situation and outputs an optimal sequence of random numbers, thereby limiting speed bias always in a small range; this can reduce unnecessary changes in the output value of the speed regulator. The feasibility and effectiveness of the proposed algorithm and control method have been demonstrated in experiments based on a 5-kW synchronous reluctance motor. [ABSTRACT FROM AUTHOR]

Objective: As a novel drug formulation, antibody drug conjugates (ADCs) are widely used in various types of cancer. However, clinically, there is a lack of attention to the CVD produced by them, as well as a lack of research on the real-world situation. Using the Food and Drug Administration Adverse Event Reporting System (FAERS) database, to ensure its clinical safety application, we analyzed post-marketing data on antitumor ADCs to identify risk factors and drugs associated with the risk of cardiovascular events., Research Design and Methods: We used OpenVigil 2.1 to conduct a database query for adverse events (AEs) reported to the FAERS database between the time the drug was launched and the second quarter of 2023. Cardiovascular adverse events (AEs) were grouped into fourteen narrow categories using the Standardized Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQs), and the reporting odds ratio (ROR) and the proportional reporting ratio (PRR) for reporting the association between different drugs and cardiovascular disease (CVD) risk were calculated., Results: In the FAERS database, 1863 AEs associated with CVD we studied were identified in patients receiving ADC therapy. Most reports came from people aged ≥65, but a significant number of cases were found to be unknown. The number of patients with antibody-drug conjugates (ADCs)-related CVD cases aged <18 years, 18-64 years, and≥ 65 years was 52 (2.79%), 586 (31.45%), and 613 (32.90%), respectively. The proportion of female patients (834, 44.77%) was higher than that of male patients (752, 40.37%). Death (770 reports), disability (9 reports), Hospitalization initial or prolonged (407 reports), and life-threatening reactions (187 reports). Of the 770 deaths reported, 103 (31.7%) were associated with brentuximab vedotin, 10 (24.4%) with sacituzumab govitecan, 22 (19.3%) with enfortumab vedotin, and 35 (34.7%) with trastuzumab emtansine.49 (41.2%) cases were associated with polatuzumab vedotin, 62 (29%) with trastuzumab deruxtecan, 423 (54.3%) with gemtuzumab ozogamicin, and 66 (38.8%) with inotuzumab ozogamicin. In a disproportionate number of SMQS, cardiac failure ( n = 277) and embolic and thrombotic events, venous ( n = 446) were the most frequently reported CVD-related AEs in ADCs., Conclusion: By mining the FAERS database, we provided relevant information on the association between ADC use and cardiovascular-associated AEs. ADCs were associated with increased cardiovascular toxicity, deserving distinct monitoring and appropriate management. Further research is needed to confirm these findings and assess causality., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Long, Li, Pan, Wang, Chen and Wang.)